Evaluation of neprilysin sequence variation in relation to CSF beta-Amyloid levels and Alzheimer disease risk

Blomqvist, M. E., McCarthy, S. E., Blennow, K., Andersson, B., Prince, J. A. (2010) Evaluation of neprilysin sequence variation in relation to CSF beta-Amyloid levels and Alzheimer disease risk. International Journal of Molecular Epidemiology and Genetics, 1 (1). pp. 47-52.

Abstract

Neprilysin (NEP) is a principal peptidase involved in the degradation of β-amyloid (Aβ), and as such its encoding gene (MME) has been the target of numerous genetic association studies on Alzheimer disease. Here, in order to attempt replication of previous findings we have investigated several single nucleotide polymorphisms (SNPs) that have been claimed to be associated with AD. A key feature of the present study is the complementary investigation of both AD risk and quantitative measures of AD severity, including cerebrospinal (CSF) fluid levels of Aβ1-42. In contrast to the effects of APOE, none of these measures are detectably influenced by genetic polymorphism in the MME region. We thus, fail to find support for previous results suggesting that MME impacts AD.

Item Type: Paper
Uncontrolled Keywords: beta-amyloid Alzheimer disease Metalloendopeptidase MME Neprilysin Polymorphism
Subjects: diseases & disorders > mental disorders > delirium dementia cognitive disorders > Alzheimer's disease
CSHL Authors:
Communities: CSHL labs > McCombie lab
Depositing User: CSHL Librarian
Date: 2010
Date Deposited: 27 Sep 2011 15:40
Last Modified: 28 Feb 2018 20:49
PMCID: PMC3076750
URI: https://repository.cshl.edu/id/eprint/15358

Actions (login required)

Administrator's edit/view item Administrator's edit/view item